The study is about trying a new medicine called XMT-2056 for people with certain types of cancer. These are cancers that have come back or have spread and show a protein called HER2. XMT-2056 is being tested in patients who have already tried other treatments without success. This is the first time it's being used in humans, and the study will find the safest dose to use. It will also see how the medicine works against the cancer.
Key Points:
- Length and Visits: The study has two parts: finding the right dose and testing how well it works. It may involve multiple visits.
- Treatment and Risks: You'll receive XMT-2056 and be monitored for any side effects to find the best dose.
- Eligibility: To join, your cancer must show HER2, and you should have tried other treatments first.
If you have another cancer needing treatment within the last 2 years or certain brain conditions, you may not be eligible. The study is open-label, meaning both doctors and patients know the treatment given. Always talk to your doctor to see if this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand